Back to News

FDA Approves Afatinib for Squamous Cell Lung Cancer

Shirish Gadgeel, MD

Shirish Gadgeel, MD

The FDA has approved afatinib (Gilotrif) for the treatment of patients with advanced squamous cell non–small cell lung cancer (NSCLC) following progression on platinum-based chemotherapy, according to to Boehringer Ingelheim, the manufacturer of the irreversible EGFR inhibitor.

The approval was based on results from the phase III LUX-Lung 8 study, which compared second-line afatinib with erlotinib (Tarceva) in patients with advanced squamous cell carcinoma of the lung. In the study, afatinib reduced the risk of both disease progression and death by 19% compared with erlotinib.

"The overall survival data and significant delay in lung cancer progression seen in the global head-to-head phase III trial demonstrated that Gilotrif is an effective new treatment option in this patient population," LUX-Lung 8 clinical trial investigator Shirish Gadgeel, MD, leader of the Thoracic Oncology Multidisciplinary Team at the Karmanos Cancer Center, said in a statement. Click here to read the full article at

Back to News

Calendar of Events
Filter By